A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer

ConclusionsTrabectedin, in combination with PLD, may have clinical benefits in Japanese patients with relapsed advanced ovarian cancer. The recommended dosage of trabectedin for further study in this population is 1.1  mg/m2 once every 21  days.Clinical trial registration number: JapicCTI-163164
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research